Optina Diagnostics

Optina’s Retinal Deep Phenotyping platform addresses the major challenges
faced by the healthcare system related to an aging population.
 
Recently, Optina was granted breakthrough device designation by the FDA for
our first indication in Alzheimer’s Disease detection which enables a dramatic
improvement in the diagnostic accuracy of dementia.
 
Our ecosystem comprised of a proprietary platform and a network of eye clinics
creates a new and efficient means for simple patient stratification. The
ecosystem allows for the collection of data rich retinal images with 30X more
information than current retinal imaging platforms.
 
Algorithm development utilizes a ground truth that is based on specifically
characterized patients from leading institutions around the world.
 
With our developing product pipeline, Optina continues to bring clarity and
accessibility to early stage diagnosis, improving the life of millions.

Company’s Keywords:

alzheimers disease, retinal imaging, medical devices, diagnostic imaging, phenotyping, dementia, artificial intelligence